KR102253526B1 - 여성 성 기능이상에 대한 브레멜라노타이드 요법 - Google Patents

여성 성 기능이상에 대한 브레멜라노타이드 요법 Download PDF

Info

Publication number
KR102253526B1
KR102253526B1 KR1020157014777A KR20157014777A KR102253526B1 KR 102253526 B1 KR102253526 B1 KR 102253526B1 KR 1020157014777 A KR1020157014777 A KR 1020157014777A KR 20157014777 A KR20157014777 A KR 20157014777A KR 102253526 B1 KR102253526 B1 KR 102253526B1
Authority
KR
South Korea
Prior art keywords
delete delete
bremelanotide
pharmaceutical composition
administration
female
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020157014777A
Other languages
English (en)
Korean (ko)
Other versions
KR20150081345A (ko
Inventor
칼 스패나
로버트 조단
제프리 디. 에델슨
Original Assignee
팔라틴 테크놀로지스 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50628268&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102253526(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 팔라틴 테크놀로지스 인코포레이티드 filed Critical 팔라틴 테크놀로지스 인코포레이티드
Publication of KR20150081345A publication Critical patent/KR20150081345A/ko
Application granted granted Critical
Publication of KR102253526B1 publication Critical patent/KR102253526B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A61K38/34—Melanocyte stimulating hormone [MSH], e.g. alpha- or beta-melanotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
KR1020157014777A 2012-11-05 2013-11-05 여성 성 기능이상에 대한 브레멜라노타이드 요법 Active KR102253526B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261722511P 2012-11-05 2012-11-05
US61/722,511 2012-11-05
US201361770535P 2013-02-28 2013-02-28
US61/770,535 2013-02-28
PCT/US2013/068386 WO2014071339A2 (en) 2012-11-05 2013-11-05 Uses of bremelanotide in therapy for female sexual dysfunction

Publications (2)

Publication Number Publication Date
KR20150081345A KR20150081345A (ko) 2015-07-13
KR102253526B1 true KR102253526B1 (ko) 2021-05-18

Family

ID=50628268

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020157014777A Active KR102253526B1 (ko) 2012-11-05 2013-11-05 여성 성 기능이상에 대한 브레멜라노타이드 요법

Country Status (23)

Country Link
US (7) US9352013B2 (enExample)
EP (1) EP2916856B2 (enExample)
JP (1) JP6567971B2 (enExample)
KR (1) KR102253526B1 (enExample)
CN (2) CN104755094A (enExample)
AU (1) AU2013337341B2 (enExample)
BR (1) BR112015009936A8 (enExample)
DK (1) DK2916856T4 (enExample)
EA (1) EA032959B9 (enExample)
ES (1) ES2701444T5 (enExample)
FI (1) FI2916856T4 (enExample)
GE (2) GEP20196947B (enExample)
HK (1) HK1211227A1 (enExample)
IL (1) IL238276B (enExample)
MX (1) MX362610B (enExample)
MY (1) MY179755A (enExample)
NZ (1) NZ707246A (enExample)
PH (1) PH12015500915A1 (enExample)
PL (1) PL2916856T5 (enExample)
SG (1) SG11201502949QA (enExample)
UA (1) UA118656C2 (enExample)
WO (1) WO2014071339A2 (enExample)
ZA (1) ZA201503128B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11590209B2 (en) 2020-01-21 2023-02-28 Palatin Technologies, Inc. Use of bremelanotide in patients with controlled hypertension
CN119074641A (zh) * 2024-09-02 2024-12-06 万邦德制药集团有限公司 一种含布雷默浪丹药物组合物、制剂及其制备方法和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009151714A2 (en) * 2008-03-24 2009-12-17 Palatin Technologies, Inc. Therapeutic for treatment of circulatory shock, ischemia, inflammatory disease and related conditions

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7235625B2 (en) * 1999-06-29 2007-06-26 Palatin Technologies, Inc. Multiple agent therapy for sexual dysfunction
US7176279B2 (en) 2000-06-28 2007-02-13 Palatin Technologies, Inc. Cyclic peptide compositions and methods for treatment of sexual dysfunction
US6579968B1 (en) * 1999-06-29 2003-06-17 Palatin Technologies, Inc. Compositions and methods for treatment of sexual dysfunction
US7022674B2 (en) 1999-12-16 2006-04-04 Eli Lilly And Company Polypeptide compositions with improved stability
JP4943622B2 (ja) * 2000-05-31 2012-05-30 ノヴォ ノルディスク アー／エス 使い捨て可能で両端が尖った注射針並びにこの使い捨て可能で両端が尖った注射針を有するインシュリン注射システム
AU2002322466B2 (en) 2001-07-11 2007-08-30 Palatin Technologies, Inc. Linear and cyclic melanocortin receptor-specific peptides
WO2006063172A2 (en) * 2004-12-09 2006-06-15 West Pharmaceutical Services, Inc. Breech loaded fixed needle syringe and automatic injection device having the same
JP5628796B2 (ja) * 2008-06-09 2014-11-19 パラティン テクノロジーズ, インコーポレイテッドPalatin Technologies, Inc. 性的不能の治療用のメラノコルチンレセプタ特異的ペプチド
US9314509B2 (en) * 2009-11-16 2016-04-19 Ipsen Pharma S.A.S. Pharmaceutical compositions of melanocortin receptor ligands
NZ702172A (en) * 2010-04-21 2016-03-31 Abbvie Biotechnology Ltd Wearable automatic injection device for controlled delivery of therapeutic agents

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009151714A2 (en) * 2008-03-24 2009-12-17 Palatin Technologies, Inc. Therapeutic for treatment of circulatory shock, ischemia, inflammatory disease and related conditions

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Palatin Technologies Inc. "Bremelanotide in Premenopausal Women With Female Sexual Arousal Disorder and/or Hypoactive Sexual Desire Disorder" Clinicaltrials.gov. NCT01382719, March 20, 2012 (v5)*
Rosen 등, International Journal of Impotence Research. 2004, 16, 135-142*

Also Published As

Publication number Publication date
PL2916856T3 (pl) 2019-02-28
ES2701444T5 (es) 2024-05-21
ES2701444T3 (es) 2019-02-22
DK2916856T4 (da) 2024-01-22
US20140378392A1 (en) 2014-12-25
KR20150081345A (ko) 2015-07-13
EA032959B1 (ru) 2019-08-30
HK1211227A1 (en) 2016-05-20
EA032959B9 (ru) 2019-11-27
US20210060120A1 (en) 2021-03-04
US9700592B2 (en) 2017-07-11
CN117860866A (zh) 2024-04-12
BR112015009936A2 (pt) 2017-07-11
ZA201503128B (en) 2016-11-30
IL238276B (en) 2020-04-30
PL2916856T5 (pl) 2024-01-29
US10286034B2 (en) 2019-05-14
EP2916856A4 (en) 2016-06-22
MY179755A (en) 2020-11-12
PH12015500915B1 (en) 2015-06-29
AU2013337341B2 (en) 2018-02-22
PH12015500915A1 (en) 2015-06-29
US9352013B2 (en) 2016-05-31
UA118656C2 (uk) 2019-02-25
WO2014071339A3 (en) 2014-06-12
CA2890081A1 (en) 2014-05-08
JP2016503406A (ja) 2016-02-04
WO2014071339A2 (en) 2014-05-08
EP2916856A2 (en) 2015-09-16
SG11201502949QA (en) 2015-06-29
US20220362328A1 (en) 2022-11-17
FI2916856T4 (fi) 2024-01-15
CN104755094A (zh) 2015-07-01
US20190216888A1 (en) 2019-07-18
MX362610B (es) 2019-01-28
US20240335502A1 (en) 2024-10-10
BR112015009936A8 (pt) 2019-09-17
DK2916856T3 (en) 2019-01-14
GEP20196947B (en) 2019-02-11
EA201590760A1 (ru) 2015-10-30
GEAP201813826A (en) 2018-10-25
EP2916856B1 (en) 2018-09-19
AU2013337341A1 (en) 2015-05-07
MX2015005486A (es) 2015-11-13
JP6567971B2 (ja) 2019-08-28
NZ707246A (en) 2019-03-29
US20150231196A1 (en) 2015-08-20
US20180085425A1 (en) 2018-03-29
IL238276A0 (en) 2015-06-30
EP2916856B2 (en) 2023-10-18

Similar Documents

Publication Publication Date Title
RU2769397C2 (ru) Композиции и способы лечения передозировки опиоидами
Brock et al. Return of spontaneous erection during long-term intracavernosal alprostadil (Caverject) treatment
US20240335502A1 (en) Uses of bremelanotide in therapy for female sexual dysfunction
HRP20020189A2 (en) Methods of using rapid-onset selective serotonin reuptake inhibitors for treating sexual dysfunction
AU2006312373B2 (en) Pharmaceutical combinations comprising testosterone in the treatment of female sexual dysfunction
US11590209B2 (en) Use of bremelanotide in patients with controlled hypertension
KR20250030479A (ko) 여성 성기능 장애 치료용 화합물
KR20200022026A (ko) 치료 방법 및 이의 약형
CA2890081C (en) Uses of bremelanotide in therapy for female sexual dysfunction
HK40108156A (zh) 用於女性性功能障碍的布雷默浪丹疗法
KR20250134096A (ko) 발기부전의 치료를 위한 화합물
HK40081935A (en) Treatment of amyotrophic lateral sclerosis
Perelman Review of Potential Role for Bremelanotide (PT-141) in Treating Female Sexual Dysfunction

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20150603

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20181105

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20200326

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20210310

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20210512

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20210512

End annual number: 3

Start annual number: 1

PG1601 Publication of registration